Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
Bellicum Pharmaceuticals, Inc. (BLCM)
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.bellicum.com/investor-overview
Company Research
Source: GlobeNewswire
Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for product registration in Europe Company on track to report final results in 2019 followed by European regulatory submission SAN DIEGO, Dec. 01, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced late interim results from its BP-004 European registration trial, suggesting that adding rivo-celTM (rivogenlecleucel, formerly BPX-501) to stem cell transplants in patients who lack a matched donor may deliver comparable outcomes to matched unrelated donor (MUD) transplants. The data were reviewed in a presentation today at the 60th Annual Meeting of the American Society of Hematology (ASH 2018) by Mattia Algeri, M.D., Cell and Gene Therapy Unit, Ospedale Bambino Gesù, Rome, Lazio, Italy. The interi
Show less
Read more
Impact Snapshot
Event Time:
BLCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCM alerts
High impacting Bellicum Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BLCM
News
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
BLCM
Sec Filings
- 3/1/24 - Form 15-12G
- 2/27/24 - Form EFFECT
- 2/27/24 - Form EFFECT
- BLCM's page on the SEC website